Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose
Authors' conclusion
To our knowledge, this is the first study to report on anti-SARS-CoV-2 spike-specific antibody kinetics postvaccination and the effect of a booster dose in a cohort of RA patients.
Study context
- Population
- Consecutive rheumatoid arthritis (RA) patients on immunosuppressive therapies, no known SARS-CoV-2 infection, vaccinated with 2 doses of BNT162b2, mRNA-1273 or ChAdOx1 nCoV-1979 completed follow-up
- Participants
- 104 patients
- Exposure
- Booster dose vs no booster dose
- Boostern = 46
- No boostern = 33reference
- Outcome
- Anti-SARS-CoV-2 spike-specific IgG antibody kinetics at 1, 3 and 6 months after the second vaccine dose
- Follow-up
- 1, 3 and 6 months
Methodological detailslongitudinal, 6-month follow-up
- Longitudinal
- 6-month follow-up
Main finding
As reported in the abstract
Anti-SARS-CoV-2 spike-specific IgG titres
- Significant decrease in titres between 1-month and 3-month postvaccination
- p<0.01
- Booster: all developed detectable IgG at 6 months, titres higher vs 1-month
- p<0.001
- Booster: titres at 6 months higher vs 3-month
- p<0.0001
- No booster: titres at 6 months decreased vs 1-month
- p<0.0001
- No booster: titres at 6 months decreased vs 3-month
- p<0.01
Observational data: associations, not effects.
Further findings
Incidence of COVID-19 disease postvaccination · 6 months
- Incidence of COVID-19 disease postvaccination, without severe forms
- 8.9%
Original publication
Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose. Clin Exp Rheumatol. Published 22 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →